InflaRx – Talk Bio

Actionable Insights Powered by AI

InflaRx Halts Rare Skin Disease Study for Vilobelimab After Futility Signal

InflaRx; vilobelimab; pyoderma gangrenosum; futility; clinical trial; COVID-19; drug development; INF904